Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Am J Clin Dermatol. 2013 Aug;14(4):291-313. doi: 10.1007/s40257-013-0028-6.
Dermatomyositis is a specific type of inflammatory myopathy with characteristic cutaneous findings. Patients may have skin disease without clinically apparent muscle disease, but this disorder is best thought of as a systemic process. Therefore, all patients with dermatomyositis skin lesions need appropriate evaluation for muscle disease, esophageal dysfunction, cardiopulmonary disease, and potential internal malignancy. There are many therapies that have been used for patients with dermatomyositis, but most are based upon case series or expert opinion rather than meta-analyses or randomized, placebo-controlled trials. Even those therapies that have been subjected to randomized, blinded, placebo-controlled trials include a mixture of patients with idiopathic inflammatory myopathy and do not utilize a validated assessment tool for measuring cutaneous disease responses. In this review, we discuss the therapies available as well as the internal associations with dermatomyositis.
皮肌炎是一种具有特征性皮肤表现的特发性炎性肌病。患者可能有皮肤疾病而无明显的肌肉疾病,但这种疾病最好被认为是一种全身性疾病。因此,所有有皮肌炎皮损的患者都需要对肌肉疾病、食管功能障碍、心肺疾病和潜在的内脏恶性肿瘤进行适当的评估。有许多治疗方法已被用于皮肌炎患者,但大多数是基于病例系列或专家意见,而不是荟萃分析或随机、安慰剂对照试验。即使那些已经经过随机、双盲、安慰剂对照试验的治疗方法也包括了特发性炎性肌病患者的混合,并且没有使用经过验证的评估工具来测量皮肤疾病的反应。在这篇综述中,我们讨论了现有的治疗方法以及与皮肌炎相关的内在联系。